NanoVibronix is a medical devices business based in the US. NanoVibronix shares (NAOV) are listed on the NASDAQ and all prices are listed in US Dollars. NanoVibronix employs 10 staff and has a trailing 12-month revenue of around $2.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.75 |
|---|---|
| 52-week range | $0.67 - $4.23 |
| 50-day moving average | $0.76 |
| 200-day moving average | $0.92 |
| Wall St. target price | $10.50 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.68 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.7502 from 2024-07-23
| 1 week (2024-07-17) | -3.26% |
|---|---|
| 1 month (2024-06-24) | -0.64% |
| 3 months (2024-04-24) | 0.03% |
| 6 months (2024-01-24) | -17.55% |
| 1 year (2023-07-24) | -76.85% |
|---|---|
| 2 years (2022-07-22) | 4.19% |
| 3 years (2021-07-23) | 2.61 |
| 5 years (2019-07-24) | 3.09 |
| Revenue TTM | $2.9 million |
|---|---|
| Gross profit TTM | $167,000 |
| Return on assets TTM | -29.3% |
| Return on equity TTM | -112.21% |
| Profit margin | -112.35% |
| Book value | $1.26 |
| Market Capitalization | $2.1 million |
TTM: trailing 12 months
We're not expecting NanoVibronix to pay a dividend over the next 12 months.
NanoVibronix's shares were split on a 1:20 basis on 8 February 2023. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NanoVibronix shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NanoVibronix shares which in turn could have impacted NanoVibronix's share price.
Over the last 12 months, NanoVibronix's shares have ranged in value from as little as $0.6685 up to $4.23. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NanoVibronix's is 1.538. This would suggest that NanoVibronix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
NanoVibronix, Inc. , through its subsidiary, NanoVibronix Ltd. , focuses on the non-invasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy in the United States, Israel, Europe, Australia, India, and internationally. The company's product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements. The company was incorporated in 2003 and is headquartered in Tyler, Texas.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.